Key Points
- CEO sold 17,922 shares at an average price of $4.11 (≈$73,659) on March 10, reducing his stake by about 1.51%, as disclosed in an SEC Form 4.
- Shares fell 19.3% to $2.76 on heavy volume; the company is unprofitable (Q4 EPS of $(0.28) missed estimates) despite $11.28M in revenue and negative margins/ROE.
- Rapid Micro reported record Q4 and full‑year 2025 revenue and provided 2026 guidance of $37M–$41M, backed by follow‑on orders from Samsung Biologics and expanded Amgen deployments, though execution and margin risk remain.
Rapid Micro Biosystems, Inc. (NASDAQ:RPID - Get Free Report) CFO Sean Wirtjes sold 7,480 shares of Rapid Micro Biosystems stock in a transaction dated Wednesday, March 11th. The stock was sold at an average price of $4.32, for a total value of $32,313.60. Following the completion of the transaction, the chief financial officer owned 556,194 shares in the company, valued at $2,402,758.08. The trade was a 1.33% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.
Rapid Micro Biosystems Price Performance
Shares of Rapid Micro Biosystems stock traded down $0.61 during midday trading on Friday, hitting $2.82. 715,869 shares of the company were exchanged, compared to its average volume of 273,783. The firm has a 50 day simple moving average of $3.98 and a 200-day simple moving average of $3.54. The company has a debt-to-equity ratio of 0.42, a current ratio of 4.23 and a quick ratio of 2.95. The firm has a market cap of $124.77 million, a P/E ratio of -2.79 and a beta of 1.38. Rapid Micro Biosystems, Inc. has a 52 week low of $1.86 and a 52 week high of $4.94.
Rapid Micro Biosystems (NASDAQ:RPID - Get Free Report) last posted its quarterly earnings results on Thursday, March 12th. The company reported ($0.28) earnings per share for the quarter, missing analysts' consensus estimates of ($0.23) by ($0.05). Rapid Micro Biosystems had a negative return on equity of 73.90% and a negative net margin of 145.11%.The business had revenue of $11.28 million for the quarter, compared to the consensus estimate of $10.93 million. Research analysts forecast that Rapid Micro Biosystems, Inc. will post -1.1 earnings per share for the current year.
Analyst Ratings Changes
Several research firms have commented on RPID. Weiss Ratings reiterated a "sell (d-)" rating on shares of Rapid Micro Biosystems in a research report on Thursday, January 22nd. Wall Street Zen upgraded Rapid Micro Biosystems from a "sell" rating to a "hold" rating in a research note on Saturday, February 14th. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Rapid Micro Biosystems presently has a consensus rating of "Hold" and an average price target of $8.00.
Get Our Latest Analysis on Rapid Micro Biosystems
Hedge Funds Weigh In On Rapid Micro Biosystems
Institutional investors have recently added to or reduced their stakes in the business. Evernest Financial Advisors LLC lifted its holdings in shares of Rapid Micro Biosystems by 355.1% in the 3rd quarter. Evernest Financial Advisors LLC now owns 200,234 shares of the company's stock worth $669,000 after acquiring an additional 156,234 shares during the last quarter. Informed Momentum Co LLC bought a new stake in shares of Rapid Micro Biosystems in the 4th quarter valued at about $224,000. Susquehanna International Group LLP boosted its holdings in Rapid Micro Biosystems by 12.6% during the 3rd quarter. Susquehanna International Group LLP now owns 58,387 shares of the company's stock valued at $195,000 after acquiring an additional 6,528 shares during the period. Dimensional Fund Advisors LP grew its position in Rapid Micro Biosystems by 37.8% during the 3rd quarter. Dimensional Fund Advisors LP now owns 55,642 shares of the company's stock worth $186,000 after acquiring an additional 15,255 shares during the last quarter. Finally, Marshall Wace LLP purchased a new position in Rapid Micro Biosystems in the 4th quarter worth approximately $182,000. 52.60% of the stock is currently owned by institutional investors.
Rapid Micro Biosystems News Roundup
Here are the key news stories impacting Rapid Micro Biosystems this week:
- Positive Sentiment: Recorded revenue growth and raised outlook: RPID reported record Q4 ($11.3M) and full‑year 2025 ($33.6M) revenue with management providing 2026 revenue guidance of $37.0M–$41.0M and expected system placements, signaling continued commercial traction and scale potential. GlobeNewswire: Record Fourth Quarter and Full-Year 2025 Financial Results
- Positive Sentiment: Large customer orders: RPID announced follow‑on multi‑system orders (Samsung Biologics) and expanded deployments (Amgen), reinforcing demand from big pharma/CDMO customers and validating the Growth Direct platform in large manufacturing networks. GlobeNewswire: Follow-on Multi‑System Order from Samsung Biologics
- Positive Sentiment: Analyst/coverage note highlights adoption: Independent analysis points to big‑pharma adoption as a key growth driver, which supports upside from recurring placements, service and consumables revenue over time. Seeking Alpha: Big Pharma Adoption Driving Growth
- Neutral Sentiment: Guidance sits near consensus but leaves execution risk: 2026 revenue range is centered near analyst expectations (~$39M midpoint) but the wide range and modest gross margin guidance (~20%) leave outcomes dependent on system placements and margin expansion. Yahoo Finance: Q4 2025 Earnings Report Preview
- Neutral Sentiment: Earnings call highlighted growth vs. pressure trade‑offs: Management framed the quarter as progress on commercial adoption but noted margin and scaling pressures—mixed messaging that can moderate near‑term enthusiasm. TipRanks: Earnings Call Balances Growth, Pressure
- Negative Sentiment: EPS missed despite revenue beat: Q4 EPS came in at ($0.28) vs. consensus ($0.23) miss, and the company remains unprofitable with negative margins—an ongoing profitability concern for investors. MarketBeat: Q4 2025 Earnings and Call
- Negative Sentiment: Recent insider selling by CEO, CFO and COO: Multiple disclosed Form 4 sales by senior executives (March filings) may amplify selling pressure or raise investor concerns about insider conviction. SEC Form 4: CEO Insider Sale
About Rapid Micro Biosystems
(
Get Free Report)
Rapid Micro Biosystems (NASDAQ: RPID) develops and commercializes automated microbial detection and contamination control solutions for the life sciences industry. Its flagship offering, the Growth Direct® System, leverages digital imaging and proprietary growth indicator plates to identify and count microorganisms more rapidly than traditional culture-based methods. The company's technology platform is designed to streamline quality control workflows in pharmaceutical, biotechnology and vaccine manufacturing settings, helping clients reduce release times and improve operational efficiency.
In addition to the Growth Direct® System, Rapid Micro Biosystems offers an integrated suite of software and consumables that support automated data capture, analysis and reporting.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
